|Day Low/High||160.05 / 162.56|
|52 Wk Low/High||156.00 / 256.80|
Hint: hedge funds love the tech sector no matter what. Here are some of the hottest picks from the hedgies.
Here's what happened in the past and what we are accomplishing now.
Our theme of the week has been to scale down in our positions with limited upside (for varying reasons) to build up our cash.
- Application Seeks to Extend Duration of Use Up to 5 Years for LILETTA -
We are effectively swapping out shares of Allergan, Apache and GE for more Amazon.
We'll sell shares of Allergan, Apache and GE, which have trended lower for a year. Plus, an announcement on our annual donation to charity!
The latest broad-market charts, plus a look at what's next for Facebook.
We could be poised for even a further advance PROVIDED that we stay oversold.
The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'
As quick as last week's selloff occurred, this rebound higher has been just as fast, and we would not be surprised to see the market retest at some point.
Net income more than doubles driven by US tax reform Underlying earnings decrease by 5% to EUR 525 million as a result of a weakening of the US dollar; expense savings and higher fee revenue...
In this tape, weakness may just be a sign of rest and better times to come.
As lawsuits tied to the opioid crisis keep piling up, Purdue Pharma is discontinuing direct sales calls to doctors. Will other opioid makers follow suit?
Jim discusses our First Data Corp exit, his interview with Broadcom's CEO, Nvidia, and his Real Money article from earlier today.
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim discusses this morning's buy of Nordstrom, Allergan's earnings from yesterday and his view on a few upcoming earning reports.
Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.
The overhang of the trough earnings year and how loss of exclusivity on drugs will play out has AGN stuck in a holding pattern.
On an earnings call, Allergan's top executive rejected the possibility of moving back to the U.S. on the heels of the new tax law.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.